Nurix Therapeutics (NASDAQ:NRIX) Insider Gwenn Hansen Sells 4,111 Shares of Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 4,111 shares of the company’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $24.36, for a total transaction of $100,143.96. Following the transaction, the insider owned 117,227 shares in the company, valued at $2,855,649.72. This represents a 3.39% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gwenn Hansen also recently made the following trade(s):

• On Wednesday, August 5th, Gwenn Hansen sold 4,356 shares of Nurix Therapeutics stock. The stock was sold at an average price of $25.00, for a total transaction of $108,900.00.
• On Thursday, July 30th, Gwenn Hansen sold 3,847 shares of Nurix Therapeutics stock. The shares were sold at an average price of $23.38, for a total value of $89,942.86.
• On Thursday, June 25th, Gwenn Hansen sold 5,394 shares of Nurix Therapeutics stock. The shares were sold at an average price of $20.00, for a total value of $107,880.00.

Nurix Therapeutics Price Performance

Shares of Nurix Therapeutics stock opened at $25.12 on Thursday. The business has a 50-day simple moving average of $20.95 and a 200 day simple moving average of $17.96. Nurix Therapeutics, Inc. has a one year low of $8.19 and a one year high of $25.40. The firm has a market capitalization of $2.61 billion, a price-to-earnings ratio of -7.28 and a beta of 1.79.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings results on Thursday, July 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.08). Nurix Therapeutics had a negative return on equity of 76.09% and a negative net margin of 928.44%.The firm had revenue of $9.04 million during the quarter, compared to the consensus estimate of $15.29 million. On average, sell-side analysts expect that Nurix Therapeutics, Inc. will post -2.84 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on NRIX. Weiss Ratings reissued a “sell (d-)” rating on shares of Nurix Therapeutics in a research report on Friday, July 17th. Wall Street Zen upgraded shares of Nurix Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, July 12th. HC Wainwright raised their price objective on shares of Nurix Therapeutics from $32.00 to $34.00 and gave the company a “buy” rating in a research note on Friday, July 10th. Truist Financial lifted their price objective on shares of Nurix Therapeutics from $32.00 to $34.00 and gave the company a “buy” rating in a report on Friday, July 10th. Finally, Jefferies Financial Group boosted their target price on shares of Nurix Therapeutics from $41.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, June 8th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $34.00.

Nurix Therapeutics News Roundup

Here are the key news stories impacting Nurix Therapeutics this week:

• Positive Sentiment: Nurix will receive a $10 million milestone payment after Sanofi initiated a Phase 1 trial of the oral STAT6 degrader SAR448272/NX-3911 for type 2 inflammatory diseases. The company has earned approximately $139 million from the Sanofi collaboration and remains eligible for about $453 million in additional milestones, plus potential royalties and a U.S. co-development option. Nurix Announces $10 Million Milestone Payment
• Positive Sentiment: The company enrolled the first patient in the registrational Phase 3 DAYBreak CLL-306 trial of bexobrutideg in relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. The study is designed to test whether bexobrutideg can outperform pirtobrutinib, a key step toward potential regulatory approval and commercialization. Nurix Announces Phase 3 DAYBreak CLL-306 Enrollment
• Positive Sentiment: Needham reaffirmed its Buy rating and maintained a $34 price target, implying substantial upside from the referenced share price. The endorsement reflects continued analyst confidence in Nurix’s pipeline and commercial potential. Needham Rating Update
• Negative Sentiment: Insiders reported additional sales: CFO Hans van Houte sold 4,761 shares for approximately $116,000, while Gwenn Hansen sold 8,467 shares across August 4–5 for roughly $209,000. The transactions were conducted under pre-arranged Rule 10b5-1 plans, reducing their significance as a bearish signal, but they still represent some near-term insider selling pressure.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Walleye Capital LLC purchased a new stake in Nurix Therapeutics in the 2nd quarter valued at $378,000. Handelsbanken Fonder AB boosted its holdings in Nurix Therapeutics by 15.7% during the 2nd quarter. Handelsbanken Fonder AB now owns 633,000 shares of the company’s stock worth $15,357,000 after acquiring an additional 86,000 shares during the last quarter. Perceptive Advisors LLC boosted its holdings in Nurix Therapeutics by 4.4% during the 1st quarter. Perceptive Advisors LLC now owns 3,710,877 shares of the company’s stock worth $57,519,000 after acquiring an additional 155,000 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Nurix Therapeutics by 8.9% in the 1st quarter. Bank of America Corp DE now owns 802,153 shares of the company’s stock worth $12,433,000 after acquiring an additional 65,595 shares in the last quarter. Finally, Stempoint Capital LP bought a new stake in shares of Nurix Therapeutics in the 1st quarter worth $4,886,000.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.